F. Hoffmann-La Roche is a global health-care company providing a broad spectrum of innovative medical solutions, operating worldwide under two division: Pharmaceuticals & Diagnostics. Roche is the leading provider of cancer treatments globally.
- In Feb 2021, X-Chem, Inc., collaborate with Genentech to deploy its proprietary DEL platform to identify novel drug-like leads against multiple oncology targets of interest to Genentech and may also conduct hit-to-lead optimization for the programs. In addition, X-Chem grants Genentech an exclusive license to an existing preclinical, small molecule oncology program, consisting of several series of novel compounds previously identified by X-Chem using its DEL platform. Financial details remains undisclosed.
- In Feb 2021, Affimed entered into a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE®) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).
- In Jan 2021, Ribometrix, Inc., and Genentech signed collaboration to discover and develop novel RNA-targeted small molecule therapeutics against several targets utilizing Ribometrix’s platform. Under the terms, Ribometrix and Genentech to collaborate on the discovery and preclinical development of programs. Genentech paid Ribometrix a $25 Mn upfront payment, and in return will receive exclusive rights to several predefined targets including an exclusive global license for the development and commercialization of molecules under this collaboration. Ribometrix will also be eligible to receive potential milestone payments exceeding $1 billion as well as tiered royalties on future global net sales of products that result from the collaboration.
- In Dec 2020, Relay Therapeutics signed worldwide license agreement with Genentech for the development and commercialization of RLY-1971, a potent inhibitor of SHP2. Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036. Thus offering combination of KRAS G12C and SHP2 inhibitors that could become a new treatment option for patients with KRAS G12C mutant tumors. Under the terms, Relay received $75 Mn in an upfront payment and is eligible to receive $25 Mn in additional near-term payments, with the option to opt in to a 50/50 U.S. profit/cost share. Relay Therapeutics retains the right to combine RLY-1971 with its selective FGFR2 and mutant-selective PI3Kα programs.
- In Nov 2020, Lead Pharma and Roche entered into a collaboration and license agreement to develop oral small molecules to treat a broad range of immune mediated diseases. Under the terms Lead Pharma and Roche will collaborate in research activities up to the selection of a pre-clinical candidate after which Roche will be responsible for further development and global commercialization. Lead Pharma will receive an upfront payment of €10 Mn and will be eligible to receive research funding and pre-clinical milestone payments; total potential payments including research, development, regulatory and sales milestones may add up to an aggregate of €260 Mn, plus royalties on worldwide sales.
- In Oct 2020, Vaccibody AS enters into worldwide license agreement with Genentech, to develop DNA-based individualized neoantigen vaccines for the treatment of cancers. Under the terms, Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for the further development and commercialization. Vaccibody to receive up to USD 715 Mn, including initial upfront and in potential milestone payments.
- In Sep 2020, Scenic Biotech and Genentech signed multi-year strategic collaboration to utilizes Scenic’s Cell-Seq platform and its proprietary data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas. The collaboration enables Genentech to select multiple targets for further development with an option to extend the collaboration. Under the terms, Scenic Biotech will receive an undisclosed upfront payment and is eligible to receive milestone payments and royalties across multiple products meeting certain pre-defined conditions. Total deal value could exceed $375 Mn USD.
- In July 2020, Roche and Blueprint Medicines signed a licensing and collaboration deal providing exclusive rights to Roche/Genentech for global co-development and co-commercialization (excluding Greater China) for pralsetinib, for the treatment of people with RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other types of thyroid cancer, as well as other solid tumors. Under the terms, Roche paid an upfront of $675 Mn in cash with an addition to a $100 Mn equity investment in Blueprint Medicines who is also eligible to receive up to $927 Mn in potential milestones, plus royalties on net product sales outside the US.
- In Jul 2020, Reverie Labs enters Multi-target collaboration agreement with Roche to advance kinase drug discovery programs. Under the terms, Reverie Labs will use its technology platform to perform virtual screening, hit-to-lead generation, and lead optimization on several kinase inhibitor discovery programs, alongside scientists at Roche and Genentech. Reverie Labs will receive an upfront payment and is eligible to receive pre-clinical, clinical, and regulatory milestone payments, as well as tiered royalties on Roche’s sales of drug candidates produced by the collaboration. Further financial details remains undisclosed.
- In May 2020, Vividion entered into license agreement with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets. Under the terms, Roche has the exclusive right to license resulting compounds at different stages of development.
- In Feb 2020, Nimble Therapeutics, Inc. signed multi-year collaboration with Genentech to accelerate discovery and development of novel peptide-based medicines for targets across a range of diseases using Nimble’s proprietary peptide synthesis, screening and optimization platform.
- In Feb 2020, Bicycle Therapeutics signed an exclusive collaboration with Genentech to develop and commercialize Bicycle®-based Immuno-oncology therapies. Under the terms, Bicycle will be responsible for discovery research and early pre-clinical development while Genentech will take care for further development and commercialization. Bicycle received $30 Mn in upfront payment with up to $1.7 billion in potential development, regulatory and commercial milestone along with royalties.
- In Sep 2019, KAHR Medical announced a clinical collaboration with Roche to evaluate KAHR Medical’s lead program, DSP107, a SIRPα-41BBL DSP, in combination with Roche’s PD-L1-blocking checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced NSCLC who are refractory to existing immune checkpoint inhibitors.
- In Jun 2019, Seven and Eight Biopharmaceuticals Inc., signed a clinical research collaboration with Roche to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against the checkpoint target of PD-L1, in treating solid tumors.
- In Feb 2019, Genentech partners with Xencor to develop and commercialize its novel IL-15 cytokine therapeutics XmAb24306.XmAb24306 is an IL-15/IL-15Rα cytokine complex engineered with Xencor’s bispecific Fc domain and Xtend™ Fc technology and is Xencor’s most advanced preclinical cytokine program. Under the terms, the companies to co-develop XmAb24306 and other potential IL-15 programs, in which the companies will share development costs and profits. Genentech will commercialize medicines worldwide, and Xencor has the option to co-promote in the United States. Additionally, the companies will engage in a two-year research program to discover new IL-15 drug candidates. Genentech paid Xencor $120 Mn in upfront, and Xencor will be eligible to receive up to $160 Mn in development milestones for the XmAb24306 program and up to $180 Mn in development milestones for each new IL-15 drug candidate.
- In Jan 2019, Adaptive Biotechnologies enter into a worldwide collaboration and license agreement with Genentech, to develop and commercialize novel neoantigen directed T-cell therapies by combining Genentech’s global cancer immunotherapy research with Adaptive’s proprietary T-cell receptor (TCR) discovery and immune profiling platform (TruTCR™) to accelerate a transformational new treatment paradigm of tailoring cellular therapy for each patient’s individual cancer. Under the terms, Adaptive received $300 Mn in an initial upfront payment and may be eligible to receive more than $2 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales.
- In Jan 2019, C4 Therapeutics extend its ongoing R&D with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. Under the terms of the expansion, Roche will have exclusive options to acquire worldwide rights to continue development and commercialize drugs arising from these programs. In addition, C4T will have the option to co-develop and co-promote in the U.S. on selected programs. C4T will receive a significant upfront payment and near-term preclinical milestones. Upon success C4T may also receive royalties and potential clinical, regulatory, and commercial milestone payments totaling over $900 Mn.
- Earlier in Jan 2016, C4 and Roche signed a strategic collaboration to develop novel treatments using C4’s Degronimid™ technology. Under the terms, C4 will initially develop TPD therapeutics for a specific set of target proteins. Roche has the option to pursue further development and commercialization. C4 will receive an undisclosed upfront payment with additional milestone payments per target. The potential value of the deal over time is greater than $750 Mn.
- In Nov 2018, Immunocore Ltd entered into a new partnership with Genentech to co-develop Immunocore’s therapeutic candidate IMC-C103C, an ImmTAC® molecule targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4). Under the terms, Immunocore will lead the first-in-human clinical trial to establish safety and preliminary efficacy of IMC-C103C as both monotherapy and in combination with atezolizumab (Tecentriq®). Genentech paid Immunocore an $100 Mn in upfront and near-term milestone payments. Also, Immunocore retains an option to continue to co-develop IMC-C103C through commercialization, or to fully license the candidate to Genentech in return for royalty and milestone payments.
- In Oct 2018, SQZ Biotech and Roche expanded their earlier partnership further to jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications. Under the terms, SQZ and Roche will jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications. SQZ may receive up to $125 Mn in upfront payment & near-term milestones; and in addition, may receive development milestone payments of over $1 billion.
Earlier, in Dec 2015, SQZ Biotech signed a deal with Roche to develop a cell therapy platform that would empower patient’s own immune cells to fight a broad range of cancers. The deal leverage SQZ’s pioneering technology to engineer B cells as a therapeutic platform for oncology. The agreement provides for over $500 Mn in upfront and potential clinical, regulatory and sales milestone-based payments for advancement of all products across all planned indications, in addition to royalties on potential future products. - In Oct 2018, GO Therapeutics signed a licensing deal with Roche to develop antibodies for cancer. Under the terms, GO received an upfront and near-term milestones of $9 Mn. GO is also eligible for up to $186 Mn in milestone payments in addition to mid single digit to low double-digit royalties on any products that might come out of the agreement.
- In Aug 2018, Affimed N.V (Nasdaq: AFMD) and Genentech collaborate to develop and commercialize novel NK cell engager-based immunotherapeutic to treat multiple cancers. Under the terms, Affimed to apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, for the generation of both NK cell and T cell-engaging antibodies for Genentech. In turn, Affimed received $96 Mn in upfront payment and is eligible to receive up to an additional $5.0 billion over time.
- In May 2018, Lodo Therapeutics signed R&D collaboration with Genentech. Under the terms, Genentech to utilize Lodo Therapeutics’ proprietary genome mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential against multiple disease-related targets of interest to Genentech. Lodo to receive an undisclosed upfront payment and is eligible to receive research, development and commercialization milestone payments up to $969 Mn based on achievement of certain predetermined milestones along with tiered-royalties on sales of certain products resulting from the collaboration.
- In Jan 2018, MacroGenics signed research collaboration and license agreement with Roche, to jointly discover and develop novel bispecific molecules to undisclosed targets by combining MacroGenics’ DART® platform and Roche’s CrossMAb and DutaFab technologies. Roche would then further develop and commercialize any such product candidate. Under the terms, MacroGenics received an upfront payment of $10 Mn and is also eligible to receive up to $370 Mn in potential milestone payments.
- In Dec 2016, ImmuNext granted Roche a worldwide, exclusive license to develop and commercialize therapeutics that agonize the V-region immunoglobulin-containing suppressor of T-cell activation (VISTA) signaling pathway, with potential milestone payments to ImmuNext under the agreement could total $400 Mn alongwith up to double digits royalties on sales of products.
- In Sep 2016, BioNTech signed worldwide strategic collaboration with Genentech, to develop mRNA cancer vaccines targeting neoantigens, based upon BioNTech’s Individualized Vaccines Against Cancer (IVAC®) MUTANOME platform. Under the terms, Genentech paid BioNTech $310 Mn in upfront and near-term milestone payments. Further, the two companies to equally share all development costs and any potential profits for certain programs under the agreement. BioNTech has the right to co-promote certain products that arise from the agreement in the United States and certain countries. Presently RO7198457/ BNT1222 vaccine is in clinical trials.
- In Sep 2016, Genentech acquired an exclusive worldwide rights, except South Korea, to develop and commercialize Hanmi’s pan- RAF inhibitor- HM95573 (now Belvarafenib/GDC-5573). Hanmi received $80 Mn as an upfront payment and is eligible to receive payments based on achievement of certain predetermined development, regulatory and commercialization milestones totaling up to $830 Mn along with tiered double digit royalties on sales.
- In Oct 2015, Arvinas entered into a license agreement with Genentech for the development of new therapeutics using Arvinas’ novel PROTAC technology. The multi-year strategic license agreement encompasses multiple disease targets. Under the terms, Arvinas received an undisclosed upfront payment and is eligible to receive development and commercialization milestone payments in excess of $650 Mn based on achievement of certain predetermined milestones.
- In Jun 2015, Roche collaborate with Amgen to evaluate the safety and efficacy of talimogene laherparepvec, Amgen’s investigational oncolytic immunotherapy, in combination with Roche’s investigational anti-PDL1 therapy atezolizumab (MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.
- In Apr 2015, Roche and Curadev Pharma Private Ltd., entered into a research collaboration and exclusive license agreement for the development and commercialization of IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) enzyme Inhibitors, that mediate cancer-induced immune suppression. Under the terms, which includes a research collaboration with Roche’s research and early development organization to further extend Curadev’s findings, Curadev will receive an upfront payment of $25 Mn and will be eligible to receive up to $530 Mn in milestone payments based on achievement of certain predetermined events.
- In March 2015, Roche and Celldex Therapeutics entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex’s CD27 targeting investigational antibody and Roche’s MPDL3280A (anti-PDL1). Under the terms, Roche will provide study drug and Celldex will be responsible for conducting and funding the clinical trials.
- In Nov 2013, Roche and Immatics Biotechnologies signed a R&D collaboration to develop tumour-associated peptide (TUMAP) cancer vaccine candidates based on Immatic’s XPRESIDENT® technology platform. Under the terms, immatics received an upfront payment of $17 Mn plus potential milestone payments that could reach values in excess of $1 billion and royalties. The most advanced cancer vaccine candidate covered by the agreement is IMA942, for the treatment of gastric cancer. Roche will be responsible for the clinical development and commercialization of all of the immunotherapies generated through this collaboration.
- In Aug 2010, Aileron entered into collaboration agreement with Roche to discover, develop and commercialize a new class of drugs called Stapled Peptide for oncology, virology, inflammation, metabolism and CNS. Aileron received $25 Mn as upfront milestone to develop the technology in five different disease targets, and if succeed it may receive uptill $1.1 billion in total.
Page 2 of 3
